{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=35",
    "query": {
      "condition": "Sars-CoV2",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 1235,
    "total_pages": 124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T03:36:31.144Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04472728",
      "title": "Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Covid-19",
        "SARS-CoV2"
      ],
      "interventions": [
        {
          "name": "BIO101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biophytis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 238,
      "start_date": "2020-08-26",
      "completion_date": "2022-06-06",
      "has_results": true,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Irvine, California • Natchitoches, Louisiana + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Natchitoches",
          "state": "Louisiana"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Johnson City",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04472728"
    },
    {
      "nct_id": "NCT07108036",
      "title": "A Study to Assess Anktiva in Patients With Long Covid-19.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID"
      ],
      "interventions": [
        {
          "name": "N-803 (IL-15 Superagonist)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-11-14",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07108036"
    },
    {
      "nct_id": "NCT05042466",
      "title": "Northwest Therapies Trauma Psilocybin Study Compassionate Use Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Trauma, Nervous System"
      ],
      "interventions": [
        {
          "name": "Trauma",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NWTraumatherapies",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "21 Years to 99 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-09-03",
      "completion_date": "2025-10-03",
      "has_results": false,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 1,
      "location_summary": "Bozeman, Montana",
      "locations": [
        {
          "city": "Bozeman",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05042466"
    },
    {
      "nct_id": "NCT04442230",
      "title": "NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Infection"
      ],
      "interventions": [
        {
          "name": "NasoVAX",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Altimmune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-10-10",
      "completion_date": "2021-02-15",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 7,
      "location_summary": "Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fayetteville",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04442230"
    },
    {
      "nct_id": "NCT05289037",
      "title": "COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (B.1.1.529)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (B.1.351)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 bivalent (wildtype and Omicron BA.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM [B.1.351]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM/D614",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM/D614+B.1.351",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.351",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.529",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.617.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1270,
      "start_date": "2022-03-30",
      "completion_date": "2023-11-27",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05289037"
    },
    {
      "nct_id": "NCT05876377",
      "title": "Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SARS-CoV-2",
        "COVID-19",
        "Post-Acute COVID-19 Syndrome"
      ],
      "interventions": [
        {
          "name": "Pfizer-BioNTech COVID-19 mRNA vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 1,
      "start_date": "2023-10-23",
      "completion_date": "2026-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05876377"
    },
    {
      "nct_id": "NCT04784767",
      "title": "PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride, USP, for injection (0.9% NaCl)",
          "type": "DRUG"
        },
        {
          "name": "50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 29,
      "start_date": "2021-04-05",
      "completion_date": "2023-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784767"
    },
    {
      "nct_id": "NCT07703475",
      "title": "A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID -19"
      ],
      "interventions": [
        {
          "name": "RVX-sCPD9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-09-26",
      "completion_date": "2027-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 4,
      "location_summary": "New York, New York • Durham, North Carolina • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07703475"
    },
    {
      "nct_id": "NCT05178173",
      "title": "Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID-19",
        "Coronavirus Infection",
        "SARS CoV 2 Infection"
      ],
      "interventions": [
        {
          "name": "Placebo Comparator: Sterile Water",
          "type": "OTHER"
        },
        {
          "name": "27% Ethanol plus essential oils",
          "type": "OTHER"
        },
        {
          "name": "0.075% Cetylpyridinium Chloride",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 230,
      "start_date": "2022-01-20",
      "completion_date": "2023-07-12",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05178173"
    },
    {
      "nct_id": "NCT04435457",
      "title": "Cardiovascular Implications of COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SARS-CoV 2",
        "SARS Pneumonia",
        "COVID-19",
        "SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere",
        "Cardiac Complication"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 42,
      "start_date": "2020-09-01",
      "completion_date": "2023-05-20",
      "has_results": false,
      "last_update_posted_date": "2023-05-23",
      "last_synced_at": "2026-10-25T03:36:31.144Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04435457"
    }
  ]
}